NanoViricides, Inc. NEW (NNVC): Price and Financial Metrics
GET POWR RATINGS... FREE!
NNVC Stock Price Chart Interactive Chart >
NNVC Price/Volume Stats
| Current price | $1.73 | 52-week high | $5.56 |
| Prev. close | $1.68 | 52-week low | $1.04 |
| Day low | $1.65 | Volume | 28,000 |
| Day high | $1.78 | Avg. volume | 239,653 |
| 50-day MA | $2.22 | Dividend yield | N/A |
| 200-day MA | $2.23 | Market Cap | 19.99M |
NanoViricides, Inc. NEW (NNVC) Company Bio
NanoViricides, Inc. is a biopharmaceutical company. The Company researches treatments for viruses such as AIDS/HIV, Hepatitis C, influenza, and Asian bird flu.
Latest NNVC News From Around the Web
Below are the latest news stories about NANOVIRICIDES INC that investors may wish to consider to help them evaluate NNVC as an investment opportunity.
Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A SolutionBenzinga - Rachel Green |
NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug StrategyNanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, provides further details on its rapid drug development strategy for Monkeypox virus. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning! |
NanoViricides shares soar 41% after announcing plans to develop a monkeypox treatmentShares of NanoViricides Inc. jumped 41.8% in premarket trading on Thursday after the company said it began developing a monkeypox treatment. There are currently no approved or authorized therapies for monkeypox, though the Food and Drug Administration said last month that it's allowing prescriptions of the antiviral Tpoxx through a compassionate-use pathway. Tpoxx is made by Siga Technologies Inc. . NanoViricides' stock has slid 33.8% so far this year, while the broader S&P 500 is down 12.8%. |
NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox VirusNanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it has begun drug development to combat the monkeypox virus. |
NNVC Price Returns
| 1-mo | -22.42% |
| 3-mo | -8.47% |
| 6-mo | -19.16% |
| 1-year | -60.68% |
| 3-year | -13.50% |
| 5-year | -92.35% |
| YTD | -53.49% |
| 2021 | 29.62% |
| 2020 | 14.34% |
| 2019 | -37.25% |
| 2018 | -77.27% |
| 2017 | -17.76% |
Loading social stream, please wait...